Expansion of Plainville, Mass., facility offers bioprocessing expertise, advanced technologies and customized support Thermo Fisher Scientific Inc., the...
Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordin...
Clinical trial will evaluate safety, tolerability and antitumor activity of Repertoire's novel off-the-shelf T cell receptor (TCR) bispecific therapy as ...
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the U.S. in pediatric low-grade gl...
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for trenibotulinumtoxinE (TrenibotE) related to manufacturing processes; ...
OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene ther...
Marks AbbVie's largest-ever capital investment in a single campus since its inception Investment demonstrates continued progress a...
10x Science, which builds frontier AI for molecular-level protein characterization across the life sciences, today announced the closing of its $4.8M seed ...
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, announced a strategic partnership with Turbine, a ...
Andelyn Biosciences, (“Andelyn”) a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (&ldqu...
Alcami Corporation (“Alcami”), a leading U.S.-based contract development and manufacturing organization (CDMO), announced it has entered into...
Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indica...
CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processi...
Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory mul...
© 2026 Biopharma Boardroom. All Rights Reserved.
